Teva launches first U.S. generic against Novartis antidiarrheal Sandostatin LAR [Seeking Alpha]
IQVIA Holdings, Inc. (IQV)
Last iqvia holdings, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
ir.iqvia.com
Company Research
Source: Seeking Alpha
antidiarrheal medication marketed by Swiss pharmaceutical giant Novartis ( NYSE: NVS OTCPK:NVSEF The injectable, known as octreotide acetate, is also indicated in the U.S. as a long-term therapy for the hormonal disorder acromegaly in addition to diarrheal conditions linked to certain tumors. According to healthcare analytics firm IQVIA ( IQV ), Sandostatin LAR generated $826M of annual sales as of July 2026. “With today's launch of octreotide acetate for injectable suspension (the generic version of Sandostatin® LAR Depot), Teva is providing patients a new option for this important treatment,” said Ernie Richardsen, SVP of Teva's ( TEVA ) U.S. Commercial Generics. TEVA's biggest revenue generator in the U.S., its generics segment, added more than $1B to its topline in Q2, implying ~16% YoY growth. Recommended For You Comments More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
IQV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IQV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IQV alerts
High impacting IQVIA Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
IQV
News
- Here's Why You Should Retain IQVIA Holdings Shares Now [Yahoo! Finance]Yahoo! Finance
- IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™Business Wire
- ConcertAI Appoints James Salitan as General Counsel [Yahoo! Finance]Yahoo! Finance
- Possible Bearish Signals With IQVIA Holdings Insiders Disposing Stock [Yahoo! Finance]Yahoo! Finance
- IQVIA Holdings Inc. (NYSE: IQV) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
IQV
Earnings
- 7/22/24 - Beat
IQV
Sec Filings
- 8/29/24 - Form 4
- 8/27/24 - Form 144
- 8/15/24 - Form SC
- IQV's page on the SEC website